[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338347-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338347-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","n6-methyladenosine-methyltransferase-component-kiaa1429-is-a-potential-target-of-cancer-therapy-review","N6-Methyladenosine Methyltransferase Component KIAA1429 Is a Potential Target of Cancer Therapy - Review","","N6-methyladenosine (m6A) is the most abundant eukaryotic RNA modification and plays a crucial role in tumorigenesis. KIAA1429 is the key scaffold component of the m6A methyltransferase complex that bridges catalytic core proteins and recruits METTL3, METTL14, and WTAP. Overexpression of KIAA1429 correlates with malignancy progression and poor prognosis and is required for tumor development. By regulating many tumor-associated genes in an m6A-dependent manner, KIAA1429 contributes to proliferation, migration, drug resistance, tumor formation, and metastasis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/n6-methyladenosine-methyltransferase-component-kiaa1429-is-a-potential-target-of-cancer-therapy-review/338347/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/n6-methyladenosine-methyltransferase-component-kiaa1429-is-a-potential-target-of-cancer-therapy-review/338347.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does KIAA1429 play in m6A methyltransferase activity?","Question",{"text":63,"@type":64},"KIAA1429 functions as a scaffold in the m6A methyltransferase complex, bridging catalytic core proteins and recruiting METTL3, METTL14, and WTAP to m6A modification sites.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is KIAA1429 considered important for cancer development?",{"text":68,"@type":64},"KIAA1429 is often overexpressed in malignancies, relates to patient prognosis, and is required for tumorigenesis. It regulates expression of tumor-associated genes in an m6A-dependent manner.",{"name":70,"@type":61,"acceptedAnswer":71},"How might targeting KIAA1429 help in cancer therapy?",{"text":72,"@type":64},"The review emphasizes recent progress showing KIAA1429 influences key malignant behaviors, including proliferation, migration, drug resistance, tumor formation, and metastasis, suggesting it as a potential anti-cancer therapeutic target.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338347,1790143779,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","biomolecules  \nReview  \nN6-Methyladenosine Methyltransferase Component KIAA1429 Is a Potential Target of Cancer Therapy  \nJunjun Huang 1, Jihua Guo 1,2 and Rong Jia 1, *  \nCitation: Huang, J.; Guo, J.; Jia, R.  \nN6-Methyladenosine Methyltransferase Component KIAA1429 Is a Potential Target of Cancer Therapy. Biomolecules 2024, 14, 1319. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biom14101319  \nAcademic Editor: Alessandro Alaimo  \nReceived: 15 September 2024  \nRevised: 11 October 2024  \nAccepted: 14 October 2024  \nPublished: 17 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan 430072, China; [junjunhuang@whu.edu.cn](junjunhuang@whu.edu.cn) (J.H.); [jihuaguo@whu.edu.cn](jihuaguo@whu.edu.cn) (J.G.)  \n2 Department of Endodontics, School & Hospital of Stomatology, Wuhan University, Wuhan 430072, China  \n* [Correspondence: jiarong@whu.edu.cn](Correspondence: jiarong@whu.edu.cn)  \nAbstract: N6-methyladenosine (m6A), the most abundant RNA modification in eukaryotes, has a crucial impact on tumorigenesis. KIAA1429 is the key component of the m6A methyltransferase complex, in which KIAA1429 functions as a scaffold to bridge the catalytic core proteins. KIAA1429 is often overexpressed in malignances, associated with patient prognosis, and required for tumorigenesis. KIAA1429 regulates the expression of a number of tumor-associated genes in an m6A-dependent manner, and thus, contributes to cell proliferation, migration, drug resistance, tumor formation and metastasis. This review focuses on recent progress in the understanding of roles and mechanisms of KIAA1429 in cancers, and offers ideas for potential anti-cancer therapeutic methods by targeting KIAA1429 .  \nKeywords: KIAA1429; m6A modification; tumorigenesis; cancer therapy  \n1. Introduction  \nN6-methyladenosine (m6A) at the N6 position of adenosine is the most abundant modification in eukaryotic messenger RNAs. The deposition of m6A is a dynamic process involving a series of factors, including “writers” and “erasers” to adjust the levels of m6A modification in RNAs continuously. Many RNA-binding proteins are involved in the recognition of m6A modification in RNAs as “readers”, and affect an RNA’s stability, alternative splicing, translation, and so on. Accumulated evidence has revealed the important roles of m6A modification in tumorigenesis [1] .  \nKIAA1429, as a writer (also called VIRMA, vir-Like m6A methyltransferase associated, virilizer), is a key component of the methyltransferase complex. It is the biggest protein in the complex, bridges the catalytic core parts of the methyltransferase complex as a scaffold [2], and recruits METTL3 (methyltransferase-like 3), METTL14 (methyltransferase-like 14), and WTAP (Wilms’ tumor 1-associating protein) to specific sites of m6A modification [3] . Knockdown of KIAA1429 significantly down-regulated the m6A modification of cellular RNA [4] . In addition to m6A modification, KIAA1429 can also regulate many other cellular processes, such as alternative polyadenylation, alternative splicing, ferroptosis, and so on. KIAA1429 is associated with polyadenylation cleavage factors CPSF5 (cleavage and polyadenylation specificity factor 5) and CPSF6 (cleavage and polyadenylation specificity factor 6) in the presence of RNA, and promotes the usage of a proximal polyadenylation site [3] .  \nIn this review, we focus on recent progress in the understanding of the roles an","cbCaipBSZ61SAtRU","https://ap.wps.com/l/cbCaipBSZ61SAtRU","pdf",1464357,12,"English","# Abstract\n# Introduction\n# Gene and Protein Structure of KIAA1429\n# (Review Scope) Roles, Mechanisms, and Therapeutic Targeting of KIAA1429 in Cancers","[{\"question\":\"What role does KIAA1429 play in m6A methyltransferase activity?\",\"answer\":\"KIAA1429 functions as a scaffold in the m6A methyltransferase complex, bridging catalytic core proteins and recruiting METTL3, METTL14, and WTAP to m6A modification sites.\"},{\"question\":\"Why is KIAA1429 considered important for cancer development?\",\"answer\":\"KIAA1429 is often overexpressed in malignancies, relates to patient prognosis, and is required for tumorigenesis. It regulates expression of tumor-associated genes in an m6A-dependent manner.\"},{\"question\":\"How might targeting KIAA1429 help in cancer therapy?\",\"answer\":\"The review emphasizes recent progress showing KIAA1429 influences key malignant behaviors, including proliferation, migration, drug resistance, tumor formation, and metastasis, suggesting it as a potential anti-cancer therapeutic target.\"}]","N6-Methyladenosine Methyltransferase Component KIAA1429 Is a Potential Target of Cancer Therapy - Review | PDF",1790023169,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d5f671e06c620fce31eb3472becc71e.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d930d3d7a0fcc14b0b630cc59fdde2f9.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/216adc6dba98bf7ced902cc24d401101.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/359d54db0f5525658a46401086159e4a.webp",980,1385]